VIA
BCRX icon

Virtus Investment Advisers’s BioCryst Pharmaceuticals BCRX Stock Holding History

Virtus Investment Advisers’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Buy
133,664
+22,135
+20% +$200K 0.31% 147
2026
Q1 		$1.06M Buy
111,529
+21,251
+24% +$165K 0.29% 136
2025
Q4 		$704K Buy
90,278
+47,548
+111% +$344K 0.19% 162
2025
Q3 		$324K Hold
42,730
– – 0.09% 238
2025
Q2 		$383K Sell
42,730
-4,509
-10% -$42K 0.13% 230
2025
Q1 		$354K Buy
+47,239
New +$381K 0.1% 226
2023
Q1 		– Sell
-23,910
Closed -$274K – 281
2022
Q4 		$274K Sell
23,910
-17,798
-43% -$222K 0.18% 159
2022
Q3 		$526K Buy
+41,708
New +$537K 0.24% 80

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Virtus Investment Advisers's BCRX Position: Q2 2026 in Review

Virtus Investment Advisers increased its BioCryst Pharmaceuticals (BCRX) stake by 20% in Q2 2026, buying an estimated $200K and bringing the position to 133,664 shares worth $1.34M. The position accounts for 0.31% of the portfolio, ranked #147.

Virtus Investment Advisers first reported a position in BCRX in Q3 2022 and has held it in 8 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Virtus Investment Advisers held 133,664 shares of BioCryst Pharmaceuticals worth $1.34M as of Q2 2026.
  • Virtus Investment Advisers bought 22,135 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $200K.
  • BioCryst Pharmaceuticals made up 0.31% of Virtus Investment Advisers's portfolio in Q2 2026, its #147 holding.
  • Virtus Investment Advisers first reported a position in BioCryst Pharmaceuticals in Q3 2022 and has held it in 8 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.